I’m a fan of Feld Thoughts and recommend that you check it out if you don’t already read it. Although the content is sometimes over my head in financial lingo, I enjoy the insights I can glean from it. My favorite past post is where Feld describes mission statements as “vapid phrases that don’t inspire […]

The U.S. District Court for the District of New Jersey has issued a summary judgment ruling that GlaxoSmithKline’s U.S. Patent Nos. 5,578,628 (the ‘628 patent) and 4,753,789 (the ‘789 patent) for Zofran ODT(R) (ondansetron) Orally Disintegrating Tablets are valid, enforceable and infringed by Kali Laboratories, Inc., a wholly-owned subsidiary of Par Pharmaceutical Companies, Inc. There […]

I have been overwhelmed with comment and trackback spam of late to the point that I stopped posting for a while as I tried to deal with this problem. I noticed that Overlawyered had the same problem. It looks like Movable Type may do something about this in a future version but I had to […]

President Bush has appointed Chris Israel as the new Coordinator of International Intellectual Property Enforcement, a position Congress created last year to coordinate law-enforcement efforts aimed at stopping international copyright infringement and to oversee a federal umbrella agency responsible for administering intellectual property law. Intellectual property law enforcement is divided among a range of agencies, […]

Today’s post comes from Guest Barista C. Lee Thomason, a registered patent attorney and senior litigator at Frost Brown Todd LLC, writing on whether or not inequitable conduct claims in a patent suit should be heard in open court, or confined to a “special office” as proposed in the draft Patent Act of 2005 (H.R. […]

According to the Center for Public Integrity, Big Pharma has certainly benefited from the more than $800 million spent since 1998 on lobbyists and political campaigns. Not exactly chump-change. While industry trade group, Pharmaceutical Research and Manufacturers of America (PhRMA) claims the money helped patients, they hired a former U.S. ambassador to Canada and his […]

There has been a lot of reporting of allegations of misconduct by U.S. researchers. The Department of Health and Human Services received 274 complaints — 50 percent higher than 2003 and the most since 1989 when the federal government established a program to deal with scientific misconduct. The federal Office of Research Integrity closed only […]

An FDA advisory panel announced that Novartis AG’s Foradil asthma drug, marketed by Schering-Plough Corp., should have a warning about the risk for worsened breathing similar to that on GlaxoSmithKline Plc’s Advair and Serevent. The drug shares the ingredient salmeterol with London-based Glaxo’s Advair and Serevent. All three medicines work by easing constriction within the […]